주식/증권
📈 긍정적
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh
요약
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.